Study of CYR-101 in Patients With Schizophrenia

Update Il y a 5 ans
Reference: NCT00861796

Woman and Man

  • | Country :
  • France
  • | organs :
  • -
  • | Specialty :
  • -

Extract

This Phase II study will test whether CYR-101, a CNS-active compound with novel pharmacological profile and devoid of dopamine D2 receptor binding properties, is efficacious when administered orally in the management of patients with a diagnosis of DSM-IV schizophrenia.


Inclusion criteria

  • Schizophrenia

Links